Kangchan Choi

Dr. Kangchan Choi

Regeneration Medicine Research Center, Yonsei University Wonju College of Medicine, Wŏnju, Gangwon, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MCMoon Jung Choi
Moon Jung Choi
YLYeon Kyung Lee
Yeon Kyung Lee
Kangchan ChoiKangchan Choi
Kangchan Choi
DLDo Hyun Lee
Do Hyun Lee
HJHwayeon Jeong
Hwayeon Jeong
YPYong Serk Park
Yong Serk Park
Triple-negative breast cancer (TNBC) cells do not contain various receptors for targeted treatment, a reason behind the poor prognosis of this disease. In this study, biocompatible theranostic erythrocyte-derived nanoparticles (EDNs) were developed and evaluated for effective early diagnosis and treatment of TNBC. The anti-cancer drug, doxorubicin (DOX), was encapsulated into the EDNs and diagnostic quantum dots (QDs) were incorporated into the lipid bilayers of EDNs for tumor bio-imaging. Then, anti-epidermal growth factor receptor (EGFR) antibody molecules were conjugated to the surface of EDNs for TNBC targeting (iEDNs). According to the confocal microscopic analyses and biodistribution assay, iEDNs showed a higher accumulation in EGFR-positive MDA-MB-231 cancers in vitro as well as in vivo, compared to untargeted EDNs. iEDNs containing doxorubicin (iEDNs-DOX) showed a stronger inhibition of target tumor growth than untargeted ones. The resulting anti-EGFR iEDNs exhibited strong biocompatibility, prolonged blood circulation, and efficient targeting of TNBC in mice. Therefore, iEDNs may be used as potential TNBC-targeted co-delivery systems for therapeutics and diagnostics.

Verified
Journal Article
Open access
PDF file
Kangchan ChoiKangchan Choi
Kangchan Choi
DLDo Hyun Lee
Do Hyun Lee
JLJi Won Lee
Ji Won Lee
JLJINSUK LEE
JINSUK LEE
YLYeon Kyung Lee
Yeon Kyung Lee
YPYong Serk Park
Yong Serk Park
MRNA vaccines have emerged as a pivotal tool in combating COVID-19, offering an advanced approach to immunization. A key challenge with these vaccines is their need for extremely-low-temperature storage, which affects their stability and shelf life. Our research addresses this issue by enhancing the stability of mRNA vaccines through a novel cationic lipid, O,O′-dimyristyl-N-lysyl aspartate (DMKD). DMKD effectively binds with mRNA, improving vaccine stability. We also integrated phosphatidylserine (PS) into the formulation to boost immune response by promoting the uptake of these nanoparticles by immune cells. Our findings reveal that DMKD-PS nanoparticles maintain structural integrity under long-term refrigeration and effectively protect mRNA. When tested, these nanoparticles containing green fluorescent protein (GFP) mRNA outperformed other commercial lipid nanoparticles in protein expression, both in immune cells (RAW 264.7 mouse macrophage) and non-immune cells (CT26 mouse colorectal carcinoma cells). Importantly, in vivo studies show that DMKD-PS nanoparticles are safely eliminated from the body within 48 h. The results suggest that DMKD-PS nanoparticles present a promising alternative for mRNA vaccine delivery, enhancing both the stability and effectiveness of these vaccines.

9 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Kangchan ChoiKangchan Choi
Kangchan Choi
HJHyorim Jeong
Hyorim Jeong
DLDo Hyun Lee
Do Hyun Lee
JLJi Won Lee
Ji Won Lee
JHJu Eun Hong
Ju Eun Hong
YPYong Serk Park
Yong Serk Park
Cancer causes over 10 million deaths annually worldwide and remains a significant global health challenge. This study investigated advanced immunotherapy strategies, focusing on mRNA vaccines that target tumor-specific antigens to activate the immune system. We developed a novel mRNA vaccine using O,O′-dimyristyl-N-lysyl aspartate (DMKD) to improve stability and phosphatidylserine (PS) to enhance antigen presentation to immune cells. This vaccine, containing melanoma-associated antigen A3 (MAGE-A3) mRNA encapsulated within lipid nanoparticles (LNPs), was evaluated for its therapeutic potential against colorectal cancer. Our findings demonstrated that MAGE-A3 mRNA-containing DMKD-PS LNPs significantly reduced tumor size and weight, effectively combating metastatic cancer. The vaccine elicited a robust immune response, increasing specific immunoglobulin and cytokine levels without causing histotoxicity in major organs. These results confirm that the DMKD-PS-based MAGE-A3 mRNA vaccine holds promise for cancer prevention and treatment.

1 July 2022 in Nanotechnology, Science and Applications
Verified
Journal Article
Open access
PDF file
MCMoon Jung Choi
Moon Jung Choi
Kangchan ChoiKangchan Choi
Kangchan Choi
DLDo Hyun Lee
Do Hyun Lee
HJHwa Yeon Jeong
Hwa Yeon Jeong
SKSeong Jae Kang
Seong Jae Kang
YPYong Serk Park
Yong Serk Park
Introduction: Avoiding phagocytic cells and reducing off-target toxicity are the primary hurdles in the clinical application of nanoparticles containing therapeutics. For overcoming these errors, in this study, nanoparticles expressing CD47 proteins inhibiting the phagocytic attack of immune cells were prepared and then evaluated as an anti-cancer drug delivery vehicle. Methods: The CD47+ cell-derived nanoparticles (CDNs) were prepared from the plasma membranes of human embryonic kidney cells transfected with a plasmid encoding CD47. And the doxorubicin (DOX) was loaded into the CDNs, and anti-EGF receptor (EGFR) antibodies were conjugated to the surface of the CDNs to target tumors overexpressing EGFR. Results: The CD47+iCDNs-DOX was successfully synthesized having a stable structure. The CD47+CDNs were taken up less by RAW264.7 macrophages compared to control CDNs. Anti-EGFR CD47+CDNs (iCDNs) selectively recognized EGFR-positive MDA-MB-231 cells in vitro and accumulated more effectively in the target tumor xenografts in mice. Moreover, iCDNs encapsulating doxorubicin (iCDNs-DOX) exhibited the highest suppression of tumor growth in mice, presumably due to the enhanced DOX delivery to tumor tissues, compared to non-targeting CDNs or CD47- iCDNs. Discussion: These results suggest that the clinical application of biocompatible cell membrane-derived nanocarriers could be facilitated by functionalization with macrophage-avoiding CD47 and tumor-targeting antibodies. Graphical Abstract:

16 January 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
SCSeungchan Choi
Seungchan Choi
JJJin‐Seok Jung
Jin‐Seok Jung
YSYie‐Sung Seo
Yie‐Sung Seo
SSSungmin Song
Sungmin Song
JHJeehye Ham
Jeehye Ham
Kangchan ChoiKangchan Choi
Kangchan Choi
Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of liver‐related morbidity driven by systemic metabolic dysregulation. The recent approval of resmetirom and the clinical success of GLP‐1 receptor agonists have heralded a new era in MASH therapy, yet a convergent understanding of the complex mechanisms of these diverse agents is lacking. This review proposes a mechanistic framework centred on the convergent signalling of AMP‐activated protein kinase (AMPK), a master regulator of hepatic energy homeostasis. We examine key metabolism‐based therapeutics—pioglitazone, GLP‐1 receptor agonists, SGLT2 inhibitors, resmetirom and statins—to delineate how distinct upstream triggers converge on AMPK. Synthesising the latest evidence, we clearly delineate how each drug class activates AMPK either indirectly—through systemic effects like weight loss and glycemic control—or via direct actions on hepatocytes. We specifically contrast the liver‐targeted action of resmetirom with the predominantly systemic effects of semaglutide and discuss the ‘epigenetic lock‐in’ hypothesis, wherein chronic metabolic stress perpetuates the disease state. Based on this framework, we propose rational strategies for combination therapy. In conclusion, this AMPK‐centric framework provides a novel lens for understanding the complex pharmacology of MASH drugs and offers a valuable clinical roadmap for personalising treatment strategies to individual patient phenotypes.

Verified
Journal Article
Open access
PDF file
MCMoon Jung Choi
Moon Jung Choi
SKSeong Jae Kang
Seong Jae Kang
YLYeon Kyung Lee
Yeon Kyung Lee
Kangchan ChoiKangchan Choi
Kangchan Choi
DLDo Hyun Lee
Do Hyun Lee
YPYong Serk Park
Yong Serk Park
Many different types of nanoparticles have been suggested for tumor-targeted theranosis. However, most systems were prepared through a series of complicated processes and could not even overcome the blood–immune barriers. For the accurate diagnosis and effective treatment of cancers, herein we suggested the lipid micellar structure capturing quantum dot (QD) for cancer theranosis. The QD/lipid micelles (QDMs) were prepared using a simple self-assembly procedure and then conjugated with anti-epidermal growth factor receptor (EGFR) antibodies for tumor targeting. As a therapeutic agent, Bcl2 siRNA-cholesterol conjugates were loaded on the surface of QDMs. The EGFR-directed QDMs containing Bcl2 siRNA, so-called immuno-QDM/siBcl2 (iQDM/siBcl2), exhibited the more effective delivery of QDs and siBcl2 to target human colorectal cancer cells in cultures as well as in mouse xenografts. The effective in vivo targeting of iQDM/siBcl2 resulted in a more enhanced therapeutic efficacy of siBcl2 to the target cancer in mice. Based on the results, anti-EGFR QDM capturing therapeutic siRNA could be suggested as an alternative modality for tumor-targeted theranosis.